Department of Urology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Chin Med J (Engl). 2013;126(9):1761-5.
Transurethral resection of the bladder tumor (TURBT) remains the gold standard for non-muscle-invasive bladder cancer (NMIBC). Laser techniques have been widely used in urology. This analysis aimed to assess the safety and efficacy of holmium resection of the bladder tumor (HoLRBT) vs. TURBT.
A systemic search of MEDLINE, Embase, Web of Science, and The Cochrane Library as well as manual bibliography searches were performed to identify the relevant studies. The pooled estimates of operation time, obturator nerve reflex rate, bladder perforation rate, bladder irrigation rate, catheterization time, hospital stay, and one- and two-year recurrence free survivals were calculated.
Five studies were enrolled into our meta-analysis. No significant difference was observed in the operation time between groups (weighted mean difference (WMD) 1.01, 95% confidential interval (95% CI) -3.52 - 5.54, P = 0.66). The significant difference in the obturator nerve reflex (OR 0.05, 95% CI 0.01 - 0.04, P = 0.004), bladder perforation (OR 0.14, 95% CI 0.03 - 0.61, P = 0.009), bladder irrigation (OR 0.13, 95% CI 0.04 - 0.45, P = 0.001), catheterization time (WMD -0.96, 95% CI -1.11 to -0.82, P < 0.00001), and hospital stay (WMD -1.46, 95% CI -1.65 to -1.27, P < 0.00001) showed advantages of HoLRBT over TURBT. The 2-year recurrence free survival rate favors the HoLRBT group (OR 1.46, 95% CI 1.02 - 2.11, P = 0.04).
As a promising technique, HoLRBT is safe and efficient, and showed several advantages over TURBT. HoLRBT can be used as an alternative procedure for TURBT in terms of low-grade papillary urothelial carcinoma or low-grade early TNM-stage urothelial carcinoma.
经尿道膀胱肿瘤切除术(TURBT)仍然是非肌肉浸润性膀胱癌(NMIBC)的金标准。激光技术已广泛应用于泌尿科。本分析旨在评估钬激光膀胱肿瘤切除术(HoLRBT)与 TURBT 的安全性和疗效。
系统检索 MEDLINE、Embase、Web of Science 和 The Cochrane Library 以及手工参考文献搜索,以确定相关研究。计算手术时间、闭孔神经反射率、膀胱穿孔率、膀胱冲洗率、导尿时间、住院时间和 1 年和 2 年无复发生存率的合并估计值。
五项研究纳入了我们的荟萃分析。两组间手术时间无显著差异(加权均数差(WMD)1.01,95%置信区间(95%CI)-3.52-5.54,P=0.66)。闭孔神经反射(OR 0.05,95%CI 0.01-0.04,P=0.004)、膀胱穿孔(OR 0.14,95%CI 0.03-0.61,P=0.009)、膀胱冲洗(OR 0.13,95%CI 0.04-0.45,P=0.001)、导尿时间(WMD-0.96,95%CI-1.11 至-0.82,P<0.00001)和住院时间(WMD-1.46,95%CI-1.65 至-1.27,P<0.00001)的显著差异表明 HoLRBT 优于 TURBT。2 年无复发生存率有利于 HoLRBT 组(OR 1.46,95%CI 1.02-2.11,P=0.04)。
作为一种有前途的技术,HoLRBT 安全有效,与 TURBT 相比具有多项优势。对于低级别乳头状尿路上皮癌或低级别早期 TNM 期尿路上皮癌,HoLRBT 可作为 TURBT 的替代方法。